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Abstract
Recombinant Towne CMV expressing luciferase under the control of CMV-DNA polymerase (POL) or the late pp28
(UL99) promoters were evaluated for potential application in high-throughput screening of anti-viral compounds.
POL-and pp28-luciferase displayed maximal expression 48 and 72 hours post infection, respectively. The pp28-
luciferase virus achieved a wider dynamic range of luciferase expression (6-7 logs) and was selected for testing of
inhibition by five anti-viral compounds. Luciferase expression highly correlated with plaque reduction and real-time
PCR. The pp28-luciferase reporter system is rapid, reproducible, and highly sensitive. It may be applied to screening
of novel anti-CMV compounds.
Background
Infection with Cytomegalovirus (CMV) continues to be
a major threat in organ transplant recipients and conge-
nitally-infected children [1,2]. Although existing sys-
temic therapies are effective in suppressing virus
replication, serious side effects and the emergence of
resistant viral strains pose significant treatment dilem-
mas [3]. The need to identify and develop new anti-
CMV compounds coincides with the advancement of
rapid, sensitive, and high-throughput methods for
screening of lead compounds. While the plaque reduc-
tion assay remains the gold-standard for screening of
anti-viral compounds, new techniques based on recom-
binant DNA technology and highly sensitive molecular
assays have recently been suggested as alternatives [4-6].
Real-time PCR, the standard of care in the management
of CMV disease in high- risk patient populations, may
also provide a sensitive tool for drug screening [7-12]
In earlier studies, a series of chloramphenicol acetyl
transferase (CAT) recombinants expressing CAT under
the control of UL54 (DNA polymerase, POL)o rU L 9 9
(pp28) promoters were constructed. The expression of
CAT in infected cells highly mimicked the expression
pattern of the endogenous UL54 and UL99 [4,13]. Thus,
these two gene promoters were selected to construct
luciferase-recombinant CMV for quatification of CMV
replication in a rapid and reproducuble way. We report
on the evaluation of two luciferase recombinant viruses
(pp28 and POL) and the correlation of the pp28-lucifer-
ase system with plaque reduction and real-time PCR in
evaluation of CMV inhibition by anti-CMV compounds.
Methods
Construction of luciferase viruses
Recombinant CMV based on the laboratory-adapted
strain, Towne, was constructed by homologous recombi-
nation in transfected-infected cells. A b- galactosidase (b
-gal)-expressing Towne virus was first constructed using
an intergenic insertion site between US9 and US10.
Prior studies in which a b-glucuronidase expression cas-
sette was inserted in this intergenic region of the labora-
tory-adapted AD169 virus revealed no alteration in
expected transcription from this region [4,14,15]. The
recombinant was genetically stable and exhibited normal
in-vitro growth characteristics. The transfer vector, pT,
was constructed from pRL120 which contains the
Towne virus HindIII T fragment [16]. A 2.0 kb BamHI-
ApaI subfragment containing US9 was ligated into
pGEM11z (Promega, Madison, WI) and the adjacent 1.3
kb ApaI-ApaI fragment containing US10 was isolated
from agarose gels and ligated into the ApaI site. DNA
sequencing confirmed the correct orientation of this
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the US9 and US10 genes, was used as the insertion site
for the b-gal expression cassette containing an SV40
promoter and polyA signal (pSVb from Clontech,
Mountain View, CA). DNA extracted from human fore-
skin fibroblasts (HFF) infected with Towne virus and
linearized transfer vector containing the expression cas-
sette were coprecipitated onto subconfluent HFF cul-
tures by the calcium phosphate method [17], followed
by a 2 min shock with 20% Dimethyl sulfoxide (DMSO)
in Minimum Essential Medium (MEM) 4 to 6 hrs later.
Virus from cultures developing cytopathic effects was
passed onto fresh HFF cultures, and examined for
b -galactosidase activity. Recombinant virus, designated
T242, was isolated from positive cultures by limiting
dilution in 96 well plates of HFF and selection of b-gal
positive wells at the highest dilutions.
To produce a recombinant virus expressing the luci-
ferase reporter gene under the control of either the pro-
moter of an early gene (POL, UL54) or a late gene
(pp28, UL99), the expression cassette of luciferase was
substituted for the b-gal cassette using the same transfer
vector (pT). Expression cassettes of luciferase under the
control of POL- or pp28-promoter were constructed by
cloning the PCR products of the upstream 500 bp of
DNA polymerase or 350 bp of pp28 genes and ligating
them into the 5’ position of the luciferase coding region.
These expression cassettes were then ligated into the
blunted BstEII site of the pT transfer vector, linearized
and used in coprecipitation experiments with the DNA
of HFF cells infected with T242. Successful replacement
of the b-gal expression cassette by the luciferase expres-
sion cassettes with loss of b-gal expression and acquisi-
tion of luciferase expression as phenotypic markers
facilitated isolation of the desired recombinants. Several
PCR sequencing reactions confirmed the correct posi-
tion and orientation of the luciferase reporter gene. The
following primers were used: primer 1- US09 forward
5’-ACCTTGAAATGGGTCGCGCTCCGCT-3’,p r i m e r
2- luciferase forward-5’-ACAAGGATATGGGCTCACT-
GAGACT-3’,p r i m e r3 :l u c i f e r a s er e v e r s e5 ’-AGTCT-
CAGTGAGCCCATATCCTTGT-3’, and primer 4- US10
reverse- 5’-GCTATCGTCGCCGGAAGGAAACCGA -3’.
Cell Culture and virus infection
HFF and human lung fibroblasts (HEL) (ATCC, CRL-
2088 and CCL-137, respectively) were propagated in
Dulbecco’s Modified Eagle Medium (DMEM) containing
10% fetal bovine serum (FBS) and used for infections
with the luciferase viruses. For assays other than plaque
reduction, 4 × 10
4 HFF cells were seeded in each well of
24-well plate one day prior to infection. Luciferase
viruses were used for infections with multiplicity of
infection (MOI) of 1.0 as previously described [18].
After 90 minutes adsorption, virus was removed, and
0.5 ml of media containing specified concentrations of
antiviral compounds was added. Infected non-treated
cells were used as positive controls; non-infected cell
lysates were used as negative controls.
Luciferase Assay
HFF cells were collected and lysed with Wizard
® SV
Lysis Buffer (Promega, Madison, WI). The lysates were
assayed for luciferase and cell viability using an auto-
mated luminescent assay (Promega, Madison, WI), and
CellTiter-Glo luminescent cell viability assay kit, respec-
tively, on GloMax
®-Multi+ Detection System (Promega,
Madison, WI) according to manufacturer’s instructions.
Plaque reduction assay
HEL cells were seeded at 3 × 10
5 cells per well in
twelve-well plates and were infected 24 hours later with
the pp28-luciferase CMV at 60 PFU/well. Following
90 minutes adsorption, the medium was aspirated from
the wells, and fresh medium containing selected drug
dilutions of ganciclovir (GCV), Foscarnet (FOS), Cyclo-
heximide (CHX), artesunate (ART), dimer sulfone carba-
mate [19] and 0.5% of carboxymethyl-cellulose were
added into triplicate wells. After incubation at 37°C for
8 days, the overlay was removed, and the monolayer was
stained with crystal violet. Plaques were counted micro-
scopically under low power (40×). Drug effects were
calculated as the percentage of reduction in number of
plaques in the presence of each drug concentration to
the number observed in the absence of drug.
Virus yield reduction assay
HFF were infected with the original Towne virus or
pp28/POL– luciferase virus at an MOI of 0.1. Culture
supernatants were collected every two days until day 10
post infection and frozen at -80°C. Collected samples
were thawed and used for titration of infectious virus by
the plaque assay.
Real-time PCR
The quantitative CMV real-time PCR assay is based on
detection of a 151bp region from the highly conserved
US17 gene [20]. The limit of detection of the assay is
100 copies/mL (3.0 copies/reaction), and the measure-
able range is 2.4-8.0 log10 copies/mL. The PCR was per-
formed using a total reaction volume 50 μL. This
included 25 μL of TaqMan 2X Universal PCR Master
Mix (Applied Biosystems, Foster City, CA), 1.5 μL each
of 10 μM primers, 1 μLo f1 0μM FAM-labeled probe,
11 μLo fd H 20, and 10 μl of template. Amplification was
performed on a 7500 Real-Time PCR System (Applied
Biosystems, Foster City, CA). PCR conditions were: 50°C
for 2 min, 95°C for 10 min, 40 cycles of 95°C for 15 s
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pared by cloning the US17 amplicon in the pCR
®2.1-
TOPO
® plasmid vector (Invitrogen, Carlsbad, CA).
Serial 10-fold dilutions of plasmid from 7.0 to 1.0 log10
copies/reaction were included with each assay and used
to establish a standard curve. Assay controls included
quantified CMV AD169 DNA (Advanced Biotechnolo-
gies Inc.) and quantified Towne CMV at 3.0 and 5.0
log10 copies/mL. Quantitative CMV data were expressed
as viral DNA copies per milliliter.
Antiviral compounds
GCV, sodium phosphonoformate (FOS) and cyclohexi-
mide (CHX) were obtained from Sigma-Aldrich
(St. Louis, MO). Artemisinin derivatives, monomeric
trioxane artesunate (ART) and trioxane dimer sulfone
carbamate were synthesized at Johns Hopkins University
(GHP), and their structural details have been provided
elsewhere [18].
Results
Luciferase constructs
Two luciferase expressing viruses were constructed with
the Towne CMV strain (Figure 1A). A recombinant b-
galactosidase (b-gal) CMV strain was first prepared as a
backbone for luciferase CMV. Recombinant b-gal virus
was isolated from positive cultures. This virus was used
in a second-round DNA recombination to generate two
luciferase-reporter CMV viruses: the luciferase gene
being under the control of either UL54 (POL)o rU L 9 9
(pp28) promoters. Successful recombinants were isolated
by loss of b-gal activity and the expression of luciferase
protein. The loss of the b-gal gene and acquisition of
t h el u c i f e r a s eg e n ei nt h ee x p e c t e dl o c a t i o nw a sc o n -
firmed by DNA sequencing (Genebank submission ID:
1420040, sequences are also available in Additional
file 1). Insertion at the specific sites was verified by PCR
sequencing (Figure 1B).
Comparison of luciferase expression by the two viral
constructs
The recombinant viruses were expected to express luci-
ferase at different stages of virus replication. The early
gene UL54 (POL) is expressed within the first 24 hours
post infection (hpi), usually later than 12 hpi [21];
whereas the true late UL99 (pp28) gene is expressed
only at or after 48 hpi. Luciferase expression by POL-
and pp28-luciferase was quantified in cell lysates at 12,
24, 36, 48, 72 hpi, and at 36, 48, 72 and 96 hpi, respec-
tively (Figure 2). Using the same cell conditions, infec-
tivity, and luciferase assay system, peak luciferase
activities measured with pp28-luciferase were 20 fold
higher than those measured with POL-luciferase. The
peak activity of pp28-luciferase was reached at 72 hpi,
followed by a plateau towards 96 hpi. POL-luciferase
reached its maximum expression at 48 hours post infec-
tion. The dynamic range of the luciferase assay using
pp28-luciferase and POL-luciferase was 50 - 5 × 10
6,
and 50 - 6 × 10
4 respectively; therefore the pp28-lucifer-
ase virus was used in subsequent experiments.
Figure 1 Construction of luciferase-recombinant CMV viruses
and confirmation of luciferase orientation by PCR. 1(A):
Construction of luciferase-recombinant Towne, insertion of
promoter and luciferase reporter between US9 and US10.
Appropriate restriction sites, the primers used for verification and
the expected size of PCR products are depicted. 1(B): PCR of pp28-
and POL-luciferase constructs. Lane 1-4: primers 1+ 4, lane 5-8:
primers 1+2, lane 9-12: primer 3+4.
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Towne virus
We evaluated whether insertion of the recombination
cassette affected the growth kinetics and production of
infectious progeny. The parent Towne virus, pp28- and
pol-luciferase Towne viruses were grown in HFF and
the production of infectious progeny was determined
every two days during 10 day course post infection. The
growth characteristics of the viruses were similar
(Figure 3). A marked increase in virus production was
observed starting 2 days post infection, and growth
kinetics was similar to previous reports [22]
Correlation of plaque reduction and luciferase expression
Parallel experiments were conducted using the same
MOI of pp28-luciferase CMV with and without anti-
C M Vc o m p o u n d s( G C V ,F O S ,A R T ,d i m e rs u l f o n ec a r -
bamate, CHX). The relative number of plaques counted
10 days post infection was compared to relative lucifer-
ase activities assayed 72 hpi (Figure 4 Table 1). The
drug concentration inhibiting 50% virus replication
(EC50) by plaque reduction and luciferase expression
was determined for each compound. For all five com-
pounds a high correlation was observed between plaque
reduction and luciferase expression (Figure 4). Data
obtained with the plaque reduction assay were similar to
previous reports (Table 1).
Inhibition of luciferase expression and DNA replication by
dimer sulfone carbamate and GCV
The supernatants from infected-treated and infected-
non treated cells were used for real-time PCR at day 3.
However, the test was not sensitive enough to detect
differences between the treatment conditions (data not
shown). Therefore, luciferase activity was compared with
real-time PCR from supernatants of infected cells 6 days
post infection. A high correlation was found between
luciferase expression, and DNA copy number (Figure 5).
Discussion
We report on a highly sensitive and objective luciferase
reporter assay for determination of CMV inhibition by
anti-viral agents. The assay, based on pp28-luciferase
recombinant CMV, can be performed 72 hpi and drug
treatment, has a large dynamic range of 6-7 logs, and is
highly reproducible. Our work also reveals a high degree
of correlation between late gene (luciferase) expression
and plaque enumeration further confirming the poten-
tial use of this assay in screening of anti-viral activities.
The susceptibility of CMV strains, laboratory-adapted
and clinical isolates, to anti-CMV compounds has tradi-
tionally been evaluated by the classic plaque assay [23].
Although this assay best reflects viral infectivity, or the
biological behavior of CMV, it suffers from several
drawbacks. The assay is time consuming; results are
usually available 8-21 days after infection depending on
the virus strain used, and counting of plaques is labor
intensive. Another disadvantage of the plaque assay is
that the amount of viral replication within a single cell
cannot always be determined. Not infrequently, the end-
point of the test shows enlarged cells (CPE) without
spread of the virus to adjacent cells (plaque).
Figure 2 Timing and expression pattern of pp28-and POL-
luciferase CMV. Luciferase expression was determined in cell-
lysates at indicated time points following infection with pp28- or
POL-luciferase with and without treatment with GCV (30 μM). Y axis-
log scale of luciferase read out; X axis- time points in hours.
Figure 3 Growth characteristics of Towne, pp28-and POL-
luciferase Towne viruses. The production of virus progeny was
determined in HFF infected with the original Towne virus, and
recombinant pp28- or POL-luciferase virus at an MOI of 0.1. Culture
supernatants were collected at the indicated days and used for
titration of infectious virus by the plaque assay. Y-axis on the left
indicates growth of progeny viruses in log scale, Y-axis on the right
indicated relative virus kinetics of the recombinant viruses as
compared to the parent Towne strain.
He et al. Virology Journal 2011, 8:40
http://www.virologyj.com/content/8/1/40
Page 4 of 7Recombinant viruses carrying different reporter genes
have been developed as alternative methods to overcome
some of the limitations of the plaque assay. A recombinant
CMV expressing b-galactosidase under the control of the
major immediate early promoter was used in a 96-well
assay [24]. Although the assay was sensitive and rapid,
background b-galactosidase activity was observed second-
ary to its expression under the control of an immediate
early gene during the initial infection. A secreted alkaline
phosphatase (SEAP) reporter gene driven by the CMV
major immediate early promoter was inserted at the US6
gene [25]. Reduction in SEAP activity under drug treat-
ment was used to determine drug sensitivity. Results of
transferring specific mutations in UL97 or POL were com-
pared with results obtained using traditional phenotyping
assays. The assay was validated for approved CMV drugs
(GCV, FOS, and CDV) that target the CMV DNA poly-
merase. The open reading frame between US9 and US10
Figure 4 Correlation of plaque reduction and luciferase expression. CMV-infected HFF were treated with GCV, FOS, CHX, ART, dimer sulfone
carbamate with the indicated drug concentrations. Luciferase expression was quantified in cell lysates 72 hpi. Plaque reduction was performed
10 days post infection. The correlation coefficient is provided for each experiment.
Table 1 Inhibition of pp28-luciferase by anti-CMV compounds using plaque reduction or luciferase assay
Compound Plaque Reduction EC50 (μM) Luciferase
EC50 (μM)
Reference
FOS 328 +/- 28 268 +/- 20 [28]
Dimer Sulfone Carbamate 0.067 +/- 0.011 0.066 +/- 0.004 [18]
ART 8.03 +/- 0.55 6.74 +/- 0.38 [29]
GCV 4.39 +/- 0.39 4.23 +/- 0.27 [30]
CHX 0.262 +/- 0.067 0.299 +/- 0.036 NA
EC50 was determined by plaque reduction assay or luciferase expression in pp28-luciferase CMV infected HFF cells. Reported values represent the means ±
standard deviations (SD) of data derived from at least three independent experiments performed in duplicate. Historical controls are provided for EC50 values
(reference column).
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strains [4,5,26]. For example, a GFP- reporter system gen-
erated with the laboratory-adapted strain AD169 was
applied successfully to both qualitative and semiquantita-
tive applications [5]. Compared to the GFP-CMV system,
the luciferase-CMV offers a highly accurate and quantita-
tive assay which is simple and easy to perform. A limited
evaluation of pp28 -luciferase CMV activity in the pre-
sence of GCV, acyclovir and papaverine, suggested its
potential application for anti-viral screen [26].
In addition to recombinant viruses, reporter cell lines
have been generated to screen for anti-CMV com-
pounds [6,27]. In one such approach, using a luciferase
reporter cell line, the promoter was activated by
immediate early proteins; therefore compounds that
inhibit CMV at later stages of infection cannot be evalu-
ated with this system [6]. Since the pp28-luciferase virus
is driven by the promoter of a true late CMV gene,
which can only occur after DNA replication and the
onset of transcription of late genes, it can be applied for
screening of compounds that target steps prior to and
during DNA replication. The pp28-luciferase system
therefore has a much wider application for drug screen-
ing compared to the reported luciferase cell line [6].
Quantification of viral genomes by real-time PCR is gen-
erally proportional to production of virus particles [7].
Application of real-time PCR for in-vitro screening of anti-
viral compounds is attractive because the assay is rapid
and highly-sensitive. However, compared to the luciferase
assay, real-time PCR is more labor-intensive. DNA copy
number measured in supernatants collected at 6 days post
infection with Towne virus correlated with luciferase activ-
ity in cell lysates at 3 and 6 days post infection. For a clini-
cal isolate, generally 10 days were required for
quantification of DNA in cell lysates [18]. Recently, a real-
time PCR assay of a conserved region in UL54 was per-
formed in cell lysates four days following infection and
treatment with compounds and showed a high correlation
with plaque reduction assay [12]. Additional studies are
needed to determine the best timing and compartment for
performance of the real-time PCR assay.
Our study reveals late CMV protein expression highly
correlates with the production of infectious progeny
(plaque assay) and DNA replication. Advantages of the
luciferase assay over the real-time PCR include: faster
turn-around time after infection, and lower cost (20
times less than real-time PCR). The luciferase assay
yielded similar data to the plaque assay, but its perfor-
mance (accuracy and rapidity) was superior. In conclu-
sion, the recombinant pp28-lucifarese fulfills important
characteristics that are required for high-throughput
screening of anti-viral compounds: rapidity, reproduci-
bility, low cost, and high sensitivity.
Additional material
Additional file 1: Sequences of the pp28, POL promoters and
luciferase in the region between US9 and US10. Several regions can
be distinguished- bold sequences are of CMV Towne, underlined
sequences are POL (sequence #1) and pp28 (sequence #2) promoters,
and the italic regions are the sequence of firefly luciferase gene.
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